Question of the Week

Question

Question :

Posted On : 04 Dec 2015

can Bosentan be used in neonatal pulmonary hypertension`` if yes what is the dose and duration ,side effect of therapy

Expert Answer :

Answer Discussion :

No answer discussion available.

Answer 1

Bosentan is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension {PAH}. It is licensed in the United States, the European Union and other countries under the trade name Tracleer.
Bosentan is a competitive antagonist of endothelin-1 at the endothelin-A {ET-A} and endothelin-B {ET-B} receptors. Under normal conditions, endothelin-1 binding of ET-A or ET-B receptors causes pulmonary vasoconstriction. By blocking this interaction, Bosentan decreases pulmonary vascular resistance. Bosentan has a slightly higher affinity for ET-A than ET-B.
Bosentan is indicated mainly for the treatment of pulmonary hypertension. In 2007, Tracleer {bosentan} was approved in the European Union also for reducing the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.
In the United States, Tracleer is indicated for the treatment of pulmonary arterial hypertension {WHO Group I} in patients with WHO Class II-IV symptoms, to improve exercise capacity and decrease the rate of clinical worsening.
Bosentan is Currently contraindicated in pregnancy because of its tetrogenic potential. Its use in NEONATES is not proven or been recommended @ this stage.

Question of the Week

Home

Partner Sites